…d blood samples from >1000 patients enrolled in the ADVANCE (Peg-interferon-beta-1a), CHAMPS and MSCRG (interferon-beta-1a), and SENTINEL (natalizumab) trials (Calabresi et al. ECTRIMS 2018; abstract 158). Baseline NfL was associated with the number of Gd-enhancing lesions and the accumulation of new T2 lesions over time. NfL was higher in patients with active disease or high brain atrophy rates; levels were low in patients with no evidence of dis…

…mod/alemtuzumab (P935) Physician behaviour: Misdiagnosis (P656); use of higher-efficacy DMDs (P868); risk tolerance (P968) Clinical issues and observations: Two-minute walk (P707); natalizumab-to-ocrelizumab switch (P933); natalizumab wearing-off effect (P877); HDL cholesterol after fingolimod/DMF (P944) Click here to view our ECTRIMS daily reports…

…CHORDS (ocrelizumab) (P635); SUNBEAM (ozanimod) (P556); biotin (P592) Real-world/database analyses: Dimethyl fumarate (P457, P576, P593, P595, P598, P641); natalizumab (P596, P597); biotin (P585); fingolimod (P591, P602) NfL: Biomarker of disability (P378); of cognitive impairment (P458, P530, P536); of MRI activity (P532) Switching studies: Injectable to oral (P548); fingolimod to alemtuzumab (P572); natalizumab to teriflunomide (P608); physicia…